This press release contains forward-looking statements, including, but not limited to, statements related to the planned commercial launch of LUVOX CR and Jazz Pharmaceuticals' continuing efforts, including manufacturing to prepare for commercial launch. Words and phrases such as "will," "are proceeding" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Jazz Pharmaceuticals' current expectations. Forward-looking statements involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to when or whether commercial launch of LUVOX CR will occur, Jazz Pharmaceuticals' ability to attain market acceptance of LUVOX CR by physicians, patients and third party payors, Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers, and scaling up manufacturing of LUVOX CR to commercial capacity. These and other risk factors are discussed under "Risk Factors," in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 9, 2007. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
(C)2008 Jazz Pharmaceuticals, Inc. SODAS(R) is a registered trademark
of Elan Pharma International Limited, Ireland, a subsidiary of Elan
Corporation, plc (NYSE; ELN) LUVOX is a registered trademark of Solvay
(1) Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled
release formulation for the treatment of
|SOURCE Jazz Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved